DAMORA THERAPEUTICS, INC. Income Tax Expense
DAMORA THERAPEUTICS, INC. (DMRA) reported Income Tax Expense of $255.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $255.00K, a 6275.00% increase year-over-year.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $42.00K, a 2000.00% increase year-over-year.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $44.00K.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2025 was $50.00K, a 21.95% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2024 was $41.00K.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2023 was $0.00.
- DAMORA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $255.00K 10-Q · filed 2026-08-10 | $297.00K 10-Q · filed 2026-08-10 | $341.00K derived: sum of 3 quarters · filed 2026-08-10 | $341.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $42.00K 10-Q · filed 2026-05-12 | $86.00K derived: sum of 2 quarters · filed 2026-05-12 | $86.00K derived: sum of 3 quarters · filed 2026-05-12 | $90.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $44.00K derived: sum of 2 quarters · filed 2026-03-19 | $48.00K derived: sum of 3 quarters · filed 2026-08-10 | $50.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $4.00K derived: sum of 2 quarters · filed 2026-08-10 | $6.00K 10-Q · filed 2025-11-06 | -$2.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-10 | $6.00K 10-Q · filed 2026-08-10 | -$2.00K derived: sum of 3 quarters · filed 2026-08-10 | $5.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-12 | -$6.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.00K derived: sum of 3 quarters · filed 2026-05-12 | $43.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.00K derived: sum of 2 quarters · filed 2026-03-19 | $41.00K derived: sum of 3 quarters · filed 2026-03-19 | $41.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $7.00K 10-Q · filed 2025-11-06 | $49.00K derived: sum of 2 quarters · filed 2025-11-06 | $49.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $42.00K 10-Q · filed 2025-08-05 | $42.00K 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-19 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-08 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-17 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |